Notable, Moffitt Momentum, Volume 2; Issue 1

REVOLUTIONARY NEW TREATMENTS FOR MELANOMA.

Moffitt researchers led clinical trials that helped fast-track the FDA approval of the first immunotherapy for patients with metastatic melanoma. Keytruda (pembrolizumab) works by blocking a cellular pathway known as PD-1, which restricts the body’s immune system from attacking melanoma cells. It is the sixth new melanoma drug to be approved by the FDA since 2011.

NEW MCKINLEY CAMPUS TO OPEN IN FALL 2015.

Moffitt’s main campus at the University of South Florida is at full capacity. A new $88.8 million, six-story, 207,000-square-foot building on North McKinley
Drive is scheduled to open in fall 2015. The facility will provide expedited surgical services for outpatient cases, expanded clinics, radiology services and other support services.

BEST PLACE TO WORK.

Moffitt has been named a “Best Place to Work” by many publications, including Working Mother Magazine, Computerworld, Florida Trend andTampa Bay Times.

WHEN YOU DONATE TO CANCER RESEARCH your gift will go directly to helping researchers and scientists develop the medicines and protocols that will advance cancer treatments and help cure patients. Simply put, your generosity will help save lives. Every gift, no matter the size, makes a difference. Now is the time to get involved and help make a difference. Visit MOFFITT.org/Giving to find out more.